Protective efficacy of major outer membrane protein-specific immunoglobulin A (IgA) and IgG monoclonal antibodies in a murine model of Chlamydia trachomatis genital tract infection.
about
Bioluminescence imaging of Chlamydia muridarum ascending infection in miceThe Role of the Immune Response in Chlamydia trachomatis Infection of the Male Genital Tract: A Double-Edged SwordRole for inducible nitric oxide synthase in protection from chronic Chlamydia trachomatis urogenital disease in mice and its regulation by oxygen free radicalsA vaccine formulated with the major outer membrane protein can protect C3H/HeN, a highly susceptible strain of mice, from a Chlamydia muridarum genital challengeOutcome of urogenital infection with Chlamydia muridarum in CD14 gene knockout mice.Using monoclonal antibodies to prevent mucosal transmission of epidemic infectious diseases.A MyD88-dependent early IL-17 production protects mice against airway infection with the obligate intracellular pathogen Chlamydia muridarum.Production of a proteolytically active protein, chlamydial protease/proteasome-like activity factor, by five different Chlamydia species.Antibodies and antibody-secreting cells in the female genital tract after vaginal or intranasal immunization with cholera toxin B subunit or conjugatesInducible nitric oxide synthase does not affect resolution of murine chlamydial genital tract infections or eradication of chlamydiae in primary murine cell culture.Sulfated polysaccharides and a synthetic sulfated polymer are potent inhibitors of Chlamydia trachomatis infectivity in vitro but lack protective efficacy in an in vivo murine model of chlamydial genital tract infection.Differential kinetics and distribution of antibodies in serum and nasal and vaginal secretions after nasal and oral vaccination of humansProtection against ascending infection of the genital tract by Chlamydia trachomatis is associated with recruitment of major histocompatibility complex class II antigen-presenting cells into uterine tissueThe atherogenic effects of chlamydia are dependent on serum cholesterol and specific to Chlamydia pneumoniae.Lack of long-lasting hydrosalpinx in A/J mice correlates with rapid but transient chlamydial ascension and neutrophil recruitment in the oviduct following intravaginal inoculation with Chlamydia muridarum.Persistence of Chlamydia trachomatis is induced by ciprofloxacin and ofloxacin in vitroEffects of azithromycin and rifampin on Chlamydia trachomatis infection in vitro.Prior genital tract infection with a murine or human biovar of Chlamydia trachomatis protects mice against heterotypic challenge infection.Immunity to murine Chlamydia trachomatis genital tract reinfection involves B cells and CD4(+) T cells but not CD8(+) T cells.Resolution of secondary Chlamydia trachomatis genital tract infection in immune mice with depletion of both CD4+ and CD8+ T cells.Immunization with the Chlamydia trachomatis mouse pneumonitis major outer membrane protein can elicit a protective immune response against a genital challengePlasmid CDS5 influences infectivity and virulence in a mouse model of Chlamydia trachomatis urogenital infection.Complement factor C5 but not C3 contributes significantly to hydrosalpinx development in mice infected with Chlamydia muridarum.Immunization with a combination of integral chlamydial antigens and a defined secreted protein induces robust immunity against genital chlamydial challenge.Chlamydia trachomatis disrupts N-cadherin-dependent cell-cell junctions and sequesters beta-catenin in human cervical epithelial cells.Immunity to murine chlamydial genital infection.A Chlamydia trachomatis-specific Th2 clone does not provide protection against a genital infection and displays reduced trafficking to the infected genital mucosaCD4+ T cells and antibody are required for optimal major outer membrane protein vaccine-induced immunity to Chlamydia muridarum genital infection.Induction of protective immunity against Chlamydia muridarum intravaginal infection with the chlamydial immunodominant antigen macrophage infectivity potentiator.Chlamydia trachomatis polymorphic membrane protein D is a species-common pan-neutralizing antigenProfiling of human antibody responses to Chlamydia trachomatis urogenital tract infection using microplates arrayed with 156 chlamydial fusion proteins.Chlamydia induces anchorage independence in 3T3 cells and detrimental cytological defects in an infection model.A Vibrio cholerae ghost-based subunit vaccine induces cross-protective chlamydial immunity that is enhanced by CTA2B, the nontoxic derivative of cholera toxin.Characterization of humoral immune responses to chlamydial HSP60, CPAF, and CT795 in inflammatory and severe trachoma.All subtypes of the Pmp adhesin family are implicated in chlamydial virulence and show species-specific function.Oviduct infection and hydrosalpinx in DBA1/j mice is induced by intracervical but not intravaginal inoculation with Chlamydia muridarum.Inducible nitric oxide synthase regulates production of isoprostanes in vivo during chlamydial genital infection in mice.The hypothetical protein CT813 is localized in the Chlamydia trachomatis inclusion membrane and is immunogenic in women urogenitally infected with C. trachomatis.A chlamydial type III-secreted effector protein (Tarp) is predominantly recognized by antibodies from humans infected with Chlamydia trachomatis and induces protective immunity against upper genital tract pathologies in mice.B cells enhance antigen-specific CD4 T cell priming and prevent bacteria dissemination following Chlamydia muridarum genital tract infection.
P2860
Q21131995-8FAE25D1-FC4D-4065-8EF6-DE747D006970Q26851537-47A8E8C7-D4A0-47B9-838A-049D048FB654Q28363828-F3B0E11C-1306-42BC-9073-83954248A408Q28391567-8A6C53E0-BB3C-4211-A50B-3E7DBF65B601Q30826170-E428E6FD-4AA2-4C66-821A-3D1C48BED1FAQ33542433-31151619-CCBA-4778-9C64-9D6CEABD59B7Q33606828-4315CCBE-D9EB-4549-BDBB-AB5A5331E207Q33716094-6CF8C8D3-0ED1-4434-A1AF-A43C2785C04BQ33750130-F56737DA-87AC-42D4-8440-24717ACA0E3FQ33750738-0B83A359-E111-4E05-9A64-4D531A2EB89CQ33751875-3C06F7C2-C7AC-43B0-A3B3-6D511420E407Q33756767-F827A393-3C54-4EBB-A3C8-9AB84422553DQ33757229-7901A3D4-D6E1-477C-A8BE-6D89F08C490DQ33843538-3340F6E1-2DF0-42C2-81FD-4A2885DDB1DBQ33899705-61532EC5-0EFA-4F09-9421-9978B5DEB2E2Q33980950-AFD1D6A4-BB00-4358-B090-B1C964249FC4Q33983273-4E207BFA-1C89-42A7-9985-2192691F7302Q34001186-B479E1AF-C609-4ED1-9072-50CED1B65F59Q34005295-DCF2BB6C-318B-4596-9D1C-1E64C5FE0FE4Q34007017-1B79B4DD-DA18-40C5-BD74-8423BE3773C7Q34009341-1F20D5FA-7CDA-4CAA-9CA4-4E2E238514F9Q34058923-B909B636-CA58-4F38-9280-2D383E8B055DQ34059023-0C70A831-CAEB-471E-82EE-96E62F54B134Q34119450-82B4689E-1944-4C90-8A5C-F625C5D5C364Q34121544-170904BE-68F2-4C03-BA41-10BA67583DF7Q34124225-60302A09-32E2-4332-A967-D59D225C8B01Q34129905-57D51E67-54DB-43C9-B2E1-C169B6733695Q34177368-FE5B64E3-2103-4EDF-AD23-0E08A641717DQ34445366-63E88F1B-7E07-4E80-B9F5-125ADDCD9BA8Q34478609-D63E2DF7-22C7-49C6-905E-9EFA22B51567Q34491620-10964DE3-A2EB-4C3E-8D73-5D66F5324269Q34545451-C5D7F52A-66E7-41A1-84E8-B7E5828AFC75Q34708547-C7C28226-F292-4BC0-AC08-3DFF2B4D075BQ34735317-28695B07-F15A-4E40-BCA2-D0CDDE6F46BEQ34870145-90D6B2EA-05C0-4B9F-90EB-F14B775C5677Q34937975-E04C6B1B-460D-44E7-B3EF-033FFE10953AQ34946110-F13C76DD-CB04-4E3F-B86A-8EAE3E1921EAQ34975886-9DB6891E-6EF1-48AA-A8DB-32607785934EQ34980175-BDA7A322-F3C2-49E7-B5E2-0450A1153E01Q35034215-94D6A351-DD3A-4550-AB5A-89721BEEAF00
P2860
Protective efficacy of major outer membrane protein-specific immunoglobulin A (IgA) and IgG monoclonal antibodies in a murine model of Chlamydia trachomatis genital tract infection.
description
1995 nî lūn-bûn
@nan
1995 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
Protective efficacy of major o ...... matis genital tract infection.
@ast
Protective efficacy of major o ...... matis genital tract infection.
@en
type
label
Protective efficacy of major o ...... matis genital tract infection.
@ast
Protective efficacy of major o ...... matis genital tract infection.
@en
prefLabel
Protective efficacy of major o ...... matis genital tract infection.
@ast
Protective efficacy of major o ...... matis genital tract infection.
@en
P2093
P2860
P1476
Protective efficacy of major o ...... omatis genital tract infection
@en
P2093
P2860
P304
P407
P577
1995-12-01T00:00:00Z